November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
April 2020 in “Trends in Immunotherapy” Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
3 citations
,
October 2012 in “DOAJ (DOAJ: Directory of Open Access Journals)” Pemetrexed with cisplatin is safer and more effective than gemcitabine with cisplatin for advanced lung cancer.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
DOPE:DOPC liposomes can improve targeted cancer drug delivery, reducing side effects and increasing effectiveness.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
5 citations
,
October 2023 in “Phytotherapy Research” Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.
32 citations
,
September 2013 in “Breast cancer research” A specific gene variant is linked to a higher risk of hair loss from chemotherapy in breast cancer patients.
522 citations
,
January 2001 in “Cancer investigation” Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
April 2010 in “Nature Reviews Urology”
April 2024 in “Canadian Journal of Ophthalmology” A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.
4 citations
,
March 2023 in “Journal of controlled release” A special gel with medicine helps prevent melanoma from coming back after surgery.
March 2025 in “Journal of Drugs in Dermatology” A new method helps manage skin side effects from hormonal cancer therapy, improving patient care.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.
May 2015 in “Cancer Research” A new treatment may prevent hair loss from chemotherapy by normalizing scalp cell death and reducing inflammation.
August 2022 in “Deleted Journal” Nutritional education reduces chemotherapy side effects and improves health in breast cancer patients.
10 citations
,
February 2019 in “The New England Journal of Medicine” Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
1 citations
,
August 2022 in “Journal of Dermatology and Dermatologic Surgery” A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
24 citations
,
March 2022 in “Journal of the American Academy of Dermatology” Adalimumab improved folliculitis decalvans in most patients.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
1 citations
,
October 2024 in “Journal of the Endocrine Society” Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.
June 2023 in “Revista de Ciências Médicas e Biológicas” Proper management of skin and hair side effects from chemotherapy improves patients' quality of life.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
December 2010 in “Cancer Prevention Research” Presurgical models can effectively and affordably screen cancer prevention agents.